Rhythm Pharmaceuticals (RYTM) Non-Current Debt: 2016-2025
Historic Non-Current Debt for Rhythm Pharmaceuticals (RYTM) over the last 1 years, with Sep 2025 value amounting to $103.4 million.
- Rhythm Pharmaceuticals' Non-Current Debt was N/A to $103.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $103.4 million, marking a year-over-year change of. This contributed to the annual value of $108.3 million for FY2024, which is 2.00% up from last year.
- According to the latest figures from Q3 2025, Rhythm Pharmaceuticals' Non-Current Debt is $103.4 million, which was down 2.46% from $106.0 million recorded in Q2 2025.
- Rhythm Pharmaceuticals' Non-Current Debt's 5-year high stood at $108.3 million during Q4 2024, with a 5-year trough of $103.4 million in Q3 2025.
- Its 3-year average for Non-Current Debt is $106.4 million, with a median of $106.1 million in 2023.
- Data for Rhythm Pharmaceuticals' Non-Current Debt shows a peak YoY increased of 2.00% (in 2024) over the last 5 years.
- Over the past 3 years, Rhythm Pharmaceuticals' Non-Current Debt (Quarterly) stood at $106.1 million in 2023, then increased by 2.00% to $108.3 million in 2024, then reached $103.4 million in 2025.
- Its Non-Current Debt was $103.4 million in Q3 2025, compared to $106.0 million in Q2 2025 and $107.9 million in Q1 2025.